NCOA6 and breast cancer: By conjugation of NRC-03 to polydopamine (pDA)-modified reduced graphene oxide (rGO) a nanoformulation with excellent NIR optical absorbance, improved stability, high biocompatibility, and improved anti-cancer efficiency (determined by a burst release of the NRC-03 peptide from NRC-03-pDA/rGO upon photothermal conditions) was obtained opening the discussion of novel NRC-containing conjugates for augmented therapy of breast cancer (Chen et al., 2019).